147 related articles for article (PubMed ID: 38529046)
1. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
Akbari A; Hadizadeh S; Heidary L
J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
Ahmad A; Sabbour H
Cardiovasc Diabetol; 2024 Mar; 23(1):99. PubMed ID: 38500154
[TBL] [Abstract][Full Text] [Related]
3. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
[TBL] [Abstract][Full Text] [Related]
4. Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.
Rodriguez-Valadez JM; Tahsin M; Masharani U; Park M; Hunink MGM; Yeboah J; Li L; Weber E; Berkalieva A; Avezaat L; Max W; Fleischmann KE; Ferket BS
J Am Heart Assoc; 2024 Feb; 13(4):e032463. PubMed ID: 38362889
[TBL] [Abstract][Full Text] [Related]
5. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO
Diabetes Obes Metab; 2024 Jul; 26(7):2787-2795. PubMed ID: 38618983
[TBL] [Abstract][Full Text] [Related]
6. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
[TBL] [Abstract][Full Text] [Related]
7. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.
Rodriguez-Valadez JM; Tahsin M; Fleischmann KE; Masharani U; Yeboah J; Park M; Li L; Weber E; Li Y; Berkalieva A; Max W; Hunink MGM; Ferket BS
Diabetes Care; 2023 Jun; 46(6):1300-1310. PubMed ID: 37220263
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
Milder DA; Milder TY; Liang SS; Kam PCA
Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
[TBL] [Abstract][Full Text] [Related]
10. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.
Hiramoto B; McCarty TR; Lodhia NA; Jenkins A; Elnaiem A; Muftah M; Flanagan R; Chan WW
Am J Gastroenterol; 2024 Jun; 119(6):1126-1140. PubMed ID: 38634551
[TBL] [Abstract][Full Text] [Related]
11. Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
Riester MR; Zullo AR; Joshi R; Daiello LA; Hayes KN; Ko D; Kim DH; Munshi M; Berry SD
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38779879
[TBL] [Abstract][Full Text] [Related]
12. Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists.
Piccini S; Favacchio G; Morenghi E; Mazziotti G; A Lania AG; Mirani M
Diabetes Res Clin Pract; 2024 Jun; 212():111689. PubMed ID: 38697297
[TBL] [Abstract][Full Text] [Related]
13. Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications.
Dixit AA; Bateman BT; Hawn MT; Odden MC; Sun EC
JAMA; 2024 May; 331(19):1672-1673. PubMed ID: 38648036
[TBL] [Abstract][Full Text] [Related]
14. Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
Mizubuti GB; Ho AM; Silva LMD; Phelan R
Curr Opin Anaesthesiol; 2024 Jun; 37(3):323-333. PubMed ID: 38390914
[TBL] [Abstract][Full Text] [Related]
15. Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study.
Su YC; Hsieh PC; Lai EC; Lin YC; Lin YC
Diabetes Metab; 2024 May; 50(4):101545. PubMed ID: 38777141
[TBL] [Abstract][Full Text] [Related]
16. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.
Rizos EC; Tagkas CF; Asimakopoulos AI; Tsimihodimos V; Anastasiou G; Rizzo M; Agouridis AP; Ntzani EE
J Diabetes Complications; 2024 May; 38(7):108781. PubMed ID: 38833853
[TBL] [Abstract][Full Text] [Related]
17. A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
Goldenberg RM
Diabetes Obes Metab; 2024 Jul; 26(7):2997-2999. PubMed ID: 38576082
[No Abstract] [Full Text] [Related]
18. Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice.
Takubo M; Watanabe K; Saito H; Kohno G; Ishihara H
Exp Clin Endocrinol Diabetes; 2024 May; ():. PubMed ID: 38626913
[TBL] [Abstract][Full Text] [Related]
19. Absolute Benefits From Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.
Bancks MP
Diabetes Care; 2023 Jun; 46(6):1143-1144. PubMed ID: 37220264
[No Abstract] [Full Text] [Related]
20. Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System.
Makunts T; Joulfayan H; Abagyan R
medRxiv; 2023 Nov; ():. PubMed ID: 38045343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
